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Presentation of Case
A 27-year-old male farmer presented
himself to an integrated health centre in
the Bankim health district of the Adamaoua
region of Cameroon with two ulcerative
lesions with undermined edges on the upper
chest and neck as well as enlarged and
indurated lymph nodes of the neck (see
Figure 1). He had not sought any traditional
treatment and indicated that the condition
had been ongoing for one month. Given the
known high prevalence of Mycobacterium
ulcerans (M. ulcerans) disease (Buruli ulcer) in
the Bankim health district [1], ulcer exu-
dates were examined for acid-fast bacilli by
Ziehl-Neelsen (ZN) staining at the local
health centre and tested positive. Based on
the positive ZN stain, a diagnosis of Buruli
ulcer (BU) was made and the treatment
recommended for BU by the World Health
Organization (WHO) [2], daily rifampicin
(600 mg p.o.) and streptomycin (1 g i.m.) for
56 days, was administered to the patient.
Additional swabs of ulcer exudates were
analyzed using the M. ulcerans–specific
IS2404 quantitative polymerase chain reac-
tion (qPCR) assay [3]. All four swabs
obtained from the patient tested negative.
Exudate swabs were also used for the
initiation of a culture on Lo¨wensein-Jensen
medium after decontamination with 2.5%
oxalic acid for 30 minutes at room temper-
ature. After 8.5 weeks of incubation at 30uC,
the optimal growth temperature of M.
ulcerans, mycobacterial growth was observed.
The cultured mycobacteria were ZN posi-
tive, but negative in the M. ulcerans–specific
IS2404 qPCR. PCR amplification [4] and
DNA sequencing of the rifampicin resis-
tance determining region (RRDR) of the
rpoB gene identified the strain as belonging
to the M. tuberculosis complex; no rifampicin
resistance conferringmutation in the RRDR
was found. A qPCR identifying a single-
nucleotide (A to C) change at position
291549724 further characterized the culti-
vated strain as belonging to Lineage 4 (Euro-
American Linage) of M. tuberculosis [5].
Spoligotyping and analysis using the SIT-
VITWEB database revealed that the strain
belonged to the ‘‘T-family’’ [6] of M.
tuberculosis, a spoligotype of Lineage 4 which
encompasses all strains that are difficult to
classify into other spoligotype families.While
the strain therefore does not belong to the
‘‘Cameroon Family’’ of TB, the obtained
spoligo type has previously been reported to
occur in Cameroon [6].
Based on this laboratory diagnosis of an
M. tuberculosis infection, the patient was re-
examined 186 days after completion of the
BU treatment. At this point, the ulcers had
fully scarred (see Figure 1). However, the
lymph nodes of the neck remained enlarged
and indurated. A chest X-ray provided no
evidence for pulmonary tuberculosis (TB),
and the patient tested negative for human
immunodeficiency virus (HIV) infection.
Given the laboratory results and the clinical
presentation, the patient was retrospective-
ly diagnosed as a case of cutaneous TB [7].
Given the insufficiency of the BU treatment
to cure TB, the patient was started on the
full regimen of the standard TB treatment
recommended by the Cameroon National
TB Control Program: two months of
isoniazid, rifampicin, ethambutol, and pyr-
azinamide followed by four months of
isoniazid and rifampicin.
Case Discussion
Ethical approval (clearance Nu 041/
CNE/DNM/09, 19/06/2009) to analyze
patient specimens was obtained from the
National Ethics Committee of Cameroon,
registered under the Nu IRB00001954.
Written informed consent from the patient
was obtained before specimens were used
for reconfirmation of clinical diagnosis and
detailed laboratory analysis.
BU disease presents with a variety of
clinical manifestations including nonul-
cerative forms such as movable subcuta-
neous nodules, plaques, and oedema,
which may eventually progress to ulcera-
tive lesions with characteristic undermined
edges. Without treatment, ulcers may
enlarge considerably and involve entire
limbs or large areas of the trunk [8]. It is
believed that mycolactone, the macrolide
toxin produced by M. ulcerans, largely
contributes to the pathogenesis of BU
disease [9]. The diversity in clinical
presentation renders clinical diagnosis
difficult. Of the four currently available
methods for laboratory reconfirmation of
BU [8], only one, ZN microscopy, is
suitable as a point-of-care diagnostic test
in the African endemic areas, which are
usually remote and rural. However, its
sensitivity is limited [10,11]. Cultivation of
the slow-growing mycobacteria, histopa-
thology, and PCR-based detection of M.
ulcerans DNA can only be performed in
central reference laboratories.
Given its wide range of clinical presen-
tations, the differential diagnosis of cutane-
ous tuberculosis, which makes up 1%–2%
of all TB cases worldwide [7,12], is also
difficult. Both infectious and noninfectious
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diseases of the skin need to be considered
when examining a potential case of cuta-
neous TB [13]. For a definite diagnosis,
histological examination, PCR, or optimal-
ly isolation of M. tuberculosis is required. All
of these diagnostic methods again require
sophisticated reference laboratories [7,12].
Once diagnosed, patients can be treated
with the regiment that is also used to treat
pulmonary TB [7]. It is remarkable that a
clinical manifestation very similar to that of
BU disease was observed in the case
presented here, althoughM. tuberculosis does
not produce a potent macrolide toxin.
For patients from BU-endemic regions,
ZN microscopy is usually accepted as
reconfirmation of the clinical diagnosis
and, to reduce costs, it has been suggested
that only ZN negative swabs should be
sent to a reference laboratory for analysis
by PCR [11]. While the vast majority of
ZN positive samples are also PCR positive,
sensitivity of PCR is much higher than
microscopy and many ZN negative sam-
ples still turn out PCR positive [11]. In
BU-endemic areas as remote as the
Bankim health district, clinical diagnosis
by local medical staff is often considered
sufficient for treatment decision. It has
been shown that if clinical diagnosis is
performed by highly trained and experi-
enced staff, more than 90% of suspected
cases can be reconfirmed by PCR [14].
However in regions where health care staff
does not regularly encounter BU cases, a
large proportion of suspected BU cases
cannot be confirmed by laboratory tests
[15]. Clinical overdiagnosis on one side,
and true BU cases missed by relying only
on ZN microscopy on the other side, can
lead to over- or undertreatment of pa-
tients, respectively. It is therefore recom-
mended that all BU cases should be
laboratory confirmed [15]. If the decision
is made to send only ZN negative swabs
for confirmation to a reference laboratory,
training of health care staff in BU
differential diagnosis becomes even more
important. Furthermore, such training
should include the clinical presentation of
other skin diseases, including other myco-
bacterial diseases. As demonstrated by the
case presented here, lymphadenopathy—
not a typical sign of BU—should lead to a
more detailed clinical examination.
Overall, the case of a misdiagnosed
patient with cutaneous TB in a BU-
endemic area presented here further
underscores the need for a simple, highly
sensitive, and specific point-of-care diag-
nostic test for BU.
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training staff on the differential diagnosis of Buruli ulcer.
N There is a pressing need for a sensitive and specific point-of-care laboratory test
for Buruli ulcer.
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